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Background: Diabetic retinopathy is a serious microvascular disorder of the retina. Vascular 
endothelial growth factor (VEGF) expression, induced by high glucose levels and hypoxia, is 
a main feature in retinopathy. The aim of this study was to evaluate the relationship between 
vitreous and serum VEGF levels and control of diabetes and microalbuminuria in patients with 
proliferative diabetic retinopathy.
Methods: Sixty-five patients were enrolled in this case-control study, comprising 30 patients 
with proliferative diabetic retinopathy (cases) and 35 patients with nonproliferative diabetic 
retinopathy (controls). The vitreous VEGF level was compared with the serum VEGF level 
in both groups. Glycosylated hemoglobin (HbA1c), microalbuminuria, serum creatinine, and 
stage of nephropathy and retinopathy were also measured in patients with proliferative diabetic 
retinopathy, and the relationship between these parameters and serum and vitreous VEGF levels 
was investigated.
Results: Mean vitreous and serum VEGF levels were significantly higher in cases compared 
with controls (P = 0.001, P = 0.011, respectively). There was also a significant correlation 
between vitreous and serum VEGF levels (P = 0.012, r = 0.453). VEGF levels in patients with 
well controlled blood glucose (P = 0.039), on drug treatment (P = 0.045) and at an early stage 
of nephropathy (P = 0.042) were significantly lower. There was a significant correlation between 
VEGF and albumin to creatinine ratio (P = 0.017, r = 0.432).
Conclusion: Serum and vitreous VEGF levels was significantly lower in patients on oral 
therapy, in those with well controlled glycemia, and in those with early-stage retinopathy. 
Administration of anti-VEGF had a good effect in reducing the progression of proliferative 
diabetic retinopathy.
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Introduction
Diabetic retinopathy is a chronic progressive sight-threatening disease of the retinal 
microvasculature associated with prolonged hyperglycemia and other conditions 
linked to diabetes mellitus, such as hypertension, and is one of the main factors 
leading to blindness, especially in developed countries.1,2 Diabetic retinopathy is 
found in 60% of people 20 years after onset of type 2 diabetes; sight-threatening 
retinopathy is found in 2.0% of people who have had diabetes for more than 5 years 
and in 15.5% of people who have had diabetes for more than 15 years.3 In the US, 
there are six million people with diabetes mellitus, 50% of whom are unaware 
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that they have the disease, and only half of these patients 
receive adequate treatment to reduce complications related 
to diabetes.4
Some adverse consequences of diabetes mellitus in the 
eye include iris neovascularization, cataract, neuropathy, 
corneal disorders, and glaucoma, but the most debilitating 
complication is retinopathy.5 Another adverse consequence of 
diabetes mellitus is diabetic nephropathy. Diabetes is a major 
cause of end-stage renal disease, and the incidence of diabetes 
is rising rapidly. In this study, we also compared serum and 
vitreous vascular endothelial growth factor (VEGF) levels 
and stages of nephropathy, ie, mild (nonspecific light micros-
copy changes and electron microscopic-proven glomerular 
basement membrane thickening/mild mesangial expansion) 
moderate (severe mesangial expansion, nodular sclerosis, 
Kimmelstiel–Wilson lesion), and severe (advanced diabetic 
glomerulosclerosis).6
Five major clinical trials provide the scientific basis of 
standards for clinical management of diabetic retinopathy, 
ie, the Diabetic Retinopathy Study (DRS, 1971–1975),7 
the Early Treatment Diabetic Retinopathy Study (ETDRS, 
1979–1990),8 the Diabetic Retinopathy Vitrectomy Study 
(DRVS, 1977–1987),9 the Diabetes Control and Complica-
tions Trial (DCCT, 1983–1993),10 and the United Kingdom 
Prospective Diabetes Study (UKPDS, 1977–1999).11
The DRS, ETDRS, and DRVS have provided guidelines 
concerning the most opportune time for intervention with 
laser surgery and vitrectomy for diabetic retinopathy. The 
DCCT and UKPDS established the benefits of intensive 
control of blood glucose levels to reduce the risk of pro-
gression of diabetic retinopathy and other complications 
of type 1 and type 2 diabetes, respectively. The modified 
ETDRS and extended Airlie House classification12,13 have 
been devised to assess the severity and extent of the various 
lesions of diabetic retinopathy.14 This modification forms the 
basis of an overall diabetic retinopathy severity scale12 that 
ranges from the absence of retinopathy to severe vitreous 
hemorrhage. Clinical approximations of these levels provide 
practical guidelines for the diagnosis and management of 
diabetic retinopathy.14
Diabetic retinopathy is classified according to the pres-
ence or absence of abnormal new vessels as nonproliferative 
(background/preproliferative) retinopathy (mild, moderate, 
severe, very severe), proliferative retinopathy (mild, mod-
erate, high-risk), and clinically significant macular edema. 
Each has a different prognosis for vision.15
The main pathogenesis of diabetic retinopathy is 
unknown, but some assumptions are made in this regard:
•	 Protein kinase C – kinases transfer the terminal high-
energy phosphate group of ATP to a site on a target 
protein. Diacylglycerol is one of the protein kinase C 
family activator molecules, intracellular concentra-
tions of which are increased during the hyperglycemia 
of diabetes. Increased protein kinase Cβ levels may be 
induced by tissue hypoxia, leading to increased VEGF 
expression, a major factor that increases proliferation of 
vascular endothelial cells leading to neovascularization 
and enhancing breakdown of the blood-retinal barrier, 
and potentially resulting in macular edema. Therefore, 
protein kinase C inhibitors may prevent the development 
of diabetic retinopathy.16
•	 Blood viscosity and platelet adhesion – some variable 
blood disorders are observed in diabetic patients that 
stimulate production of VEGF, such as increased con-
centrations and reduced flexibility of red blood cells, and 
reduction in accumulation and adhesion of platelets and 
endothelial injuries, leading to retinal ischemia.17
•	 Aldose reductase and angiogenesis factors – an increase 
in the level of blood sugar has its own physiological, 
structural, and anatomical effects on the capillaries. 
A continuous increase in blood sugar can lead to an aldose 
reductase shunt in some tissues, the main effect of which 
is to produce alcohol from sugar. The alcohol produced 
has an adverse effect on intramural capillary pericytes, 
leading to incompetence of the vascular wall and the 
vessel microaneurysms seen as early changes in diabetic 
retinopathy. These microaneurysms are the main cause 
of retinal hemorrhage (flame-like or blot and dot).18
Damage to the vessel wall changes the structure of the 
blood-retinal barrier and also makes the retinal blood ves-
sels more permeable.19 Macular edema occurs when the 
damaged blood vessels leak fluid (exudate) onto the macula, 
causing blurred vision. Macular edema is the main cause of 
vision disturbance in patients with nonproliferative diabetic 
retinopathy, but it can also occur in PDR.20 Retina ischemia 
as a result of blood vessel damage is the main stimulus for 
producing VEGF leading to angiogenesis and increased blood 
vessel permeability.21–23
A clear association has been demonstrated between VEGF 
and diabetic retinopathy, and the ability to identify biomarkers 
may be helpful in the diagnosis of severity and progression of 
PDR, especially in its early stages, to reduce the complications 
and psychological distress experienced by these patients. The 
aim of this study was to evaluate the relationship between 
serum and vitreous VEGF levels and control of diabetes and 
microalbuminuria in patients with PDR.
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Methods and materials
In this descriptive analytical study, vitreous and blood samples 
were collected from patients who were admitted to Tabriz 
Nikoukari Educational Hospital and underwent vitrectomy. 
Before taking samples from patients, the study protocol 
was approved by the hospital research ethics committee and 
informed consent was obtained from each patient.
Thirty patients with PDR and 35 patients with nonpro-
liferative diabetic retinopathy were randomly selected and 
included in this study. The case group included patients with 
PDR who required vitrectomy for long-term vitreous hemor-
rhage and/or tractional retinal detachment and patients with 
active retinopathy leading to vitreous hemorrhage. This group 
also included patients without active retinopathy. The control 
group included patients with nondiabetic vitreous hemor-
rhage that required vitrectomy (due to ischemic v  ascular 
disease, such as central retinal or branch vein occ  lusion). 
Patients with retinal ischemia due to other pathologies were 
excluded. The diagnostic criteria for detecting diabetic 
retinopathy was based on the guidelines of the American 
Diabetes Association.24
Vitreous fluid and whole blood samples were taken from 
all patients and after separation were maintained at −70°C 
until analyzed. Patient information, including age, gender, 
duration of diabetes (less or more than 10 years), glycosylated 
hemoglobin (HbA1c) level, type of diabetes, type of diabetic 
treatment, hypertension, nephropathy stage, glycemic c  ontrol 
(poor, HbA1c .8; moderate, 7–8; well, ,7), albumin to 
c  reatinine ratio (ACR), and vitreous VEGF were recorded.
VEGF measured by immunoassay
VEGF in vitreous fluid and serum was measured by enzyme-
linked immunosorbent assay using a kit from R&D Systems 
(Minneapolis, MN). Initially, 100 µL of RDW1 assay solu-
tion was put into the microplate, then 100 µL of a standard 
solution of serum and vitreous fluid were added to the 
microplate and incubated for 2 hours at room temperature. 
After three rinses with a special solution, 200 µL of conjugate 
was added and reincubated at room temperature, and washed 
three times; 200 µL of substrate was added and centrifuged 
at 25 rpm, and then incubated. Finally, 50 µL of stop solu-
tion was added and the plates were read at a wavelength of 
450–570 nm.
Measurement of HbA1c
A 10 mL venous blood sample was taken from patients 
fasted for 8–12 hours. Measurement of fasting blood sugar 
was done by a glucose oxidase method using a kit from Zist 
Shimi Corporation, Tehran, Iran. High-performance liquid 
chromatography (HPLC) was used for measurement of HbA1c 
using a Nycocard system (Oslo, Norway). In summary, this 
method uses ion-exchange liquid chromatography with 
gradient washing for separation of HbA1c from hemolytic 
whole blood. For measurement of HbA1c, 5 µL of whole 
blood with ethylenediamine was added to 1 mL of hemolytic 
solution and then optical absorption of hemoglobin fractions, 
collected by eliminating background material, was read 
in the optical wavelength of 4.5 nm. Sediment diagnostic 
methods were used for measurement of serum creatinine 
(Jaffe method), proteinuria, and albuminuria. Measurement 
of proteinuria and albuminuria was performed using morn-
ing urine samples.
Statistical analysis
The data obtained were expressed as the mean ± standard 
deviation and also as the frequency and percentage. The data 
were analyzed by SPSS software (v 15; SPSS Inc, Chicago, 
IL). Quantitative variables were compared using Student’s 
t-test (independent samples). Comparison of the qualitative 
variables (categorical) was done using contingency tables 
and the Chi-square test or Fisher’s Exact test depending on 
conditions. Correlations were tested using Spearman’s rank 
correlation coefficients. Statistical significance was set at 
P # 0.05.
Results
Sixty-five patients (30 patients in the case group and 35 
patients in the control group) were enrolled in this study. The 
mean age was 56 ± 10 (range 37–83) years in the cases and 
35–80 years in the controls. There was no significant differ-
ence with respect to demographic features, including age and 
gender, between the two groups (P = 0.891 and P = 0.656, 
respectively). Nineteen cases were male and 11 were female. 
Among the cases, 16 (53.3%) were smokers, two (6.7%) had 
type 1 diabetes, and 28 (93.3%) had type 2 diabetes. The mean 
vitreous VEGF level in the cases was lower than in controls 
(383.10 ± 107.48 pg/mL vs 24.81 ± 1.85 pg/mL); this differ-
ence was statistically significant (P = 0.001; 95% confidence 
interval [CI]: 159.66–556.91). The mean serum VEGF level 
in the cases was lower than in the controls (515.12 ± 44.8 vs 
343.58 ± 46.41); this difference was statistically significant 
(P = 0.01; 95% CI: 41.46–301.60, Table 1).
Mean HbA1C in the cases was 7.85 ± 60, and there 
was no statistically significant correlation between HbA1c 
and serum (P = 0.403, r = 0.158) or vitreous (P = 0.837, 
r = 0.039) VEGF levels (Table 2). Mean serum HbA1c in 




Vitreous and serum VEGF levels in diabeticsClinical Ophthalmology 2012:6
diabetic patients on insulin therapy (12 patients, 40%) was 
7.87 ± 0.52 and in patients on oral therapy (glibenclamide, 
metformin, 18 patients, 60%) was 7.84 ± 0.66 (P = 0.895; 
95% CI: −0.43–0.50). There was no significant difference 
between these two types of treatment in this regard.
The mean serum VEGF level in patients on insulin 
therapy was 623.94 ± 139.51 and in those on oral therapy 
was 442.57 ± 276.28, ie, the serum VEGF level on oral 
therapy was significantly lower compared with patients on 
insulin (P = 0.045; 95% CI: 3.97–358.74). However, there 
was no significant difference in the mean vitreous VEGF 
level between patients on insulin therapy (264.98 ± 167.94) 
and those on oral agents (461.85 ± 746.00, P = 0.379; 95% 
CI: –647.93–254.09).
The PDR patients were then divided into three groups 
with respect to glycemia, ie, poorly controlled (n = 15), mod-
erately controlled (n = 13), and well controlled (n = 2).
A significantly lower serum VEGF level was observed 
in the group with good glycemic control (P = 0.039), but 
there was no statistically significant difference in the vitreous 
VEGF level between the three groups (Table 3).
We also divided the PDR patients into three groups 
according to their stage of nephropathy, ie, mild (n = 2, 
6.7%), moderate (n = 17, 56.7%), or severe (n = 11, 36.7%). 
Serum VEGF levels were significantly lower in the patients 
with mild nephropathy (P = 0.042). However, there was no 
significant difference in the vitreous VEGF level between 
the three groups (P = 0.319, Table 4). Further, with respect 
to stage of retinopathy, patients with PDR were divided into 
three groups, ie, mild (n = 8, 26.7%), moderate (n = 14, 
46.7%), or severe (n = 8, 26.7%). As shown in Table 5, there 
was no significant difference in serum and vitreous VEGF 
levels (P = 0.601 and P = 0.063, respectively).
Mean levels of albuminuria, serum creatinine, and 
urinary ACR in the cases were 249.43 ± 97.91 mg/dL, 
1.33 ± 0.50 mg/dL, and 191.53 ± 69.70 mg/dL, respectively. 
There was a significant correlation between serum VEGF 
levels and ACR (P = 0.017, r = 0.432), but not between serum 
VEGF levels and albuminuria (P = 0.414, r = 0.155). There was 
also no significant correlation between vitreous VEGF levels 
and albuminuria (P = 0.917, r = −0.020) or ACR (P = 0.844, 
r = 0.038). We also compared serum and vitreous VEGF levels 
with duration of diabetes in the cases (Table 6). There was no 
significant correlation between serum VEGF levels in patients 
with diabetes for less than 10 years and those with diabetes for 
more than 10 years (P = 0.908; 95% CI: −220.24–246.93).
Discussion
In this study, we compared serum and vitreous VEGF levels 
in patients with PDR and nondiabetic retinopathy. Mean 
serum and vitreous VEGF levels in patients with PDR 
were 515.12 ± 245.55 pg/mL and 383.10 ± 588.69 pg/mL, 
respectively, and in patients with nonproliferative diabetic 
retinopathy were 343.58 ± 274.55 pg/mL and 24.81 ± 10.97 
pg/mL, respectively. Both serum and vitreous VEGF levels 
were significantly higher than normal in diabetic patients 
(P = 0.011 and P = 0.001, respectively).
Funatsu et al compared 57 patients with PDR and 16 
controls and found mean vitreous VEGF levels of 1135.2 
pg/mL and 19.3 pg/mL, respectively. This difference was 
statistically significant.25 Hernandez et al compared 20 
patients with PDR and 20 controls, and reported signifi-
cantly higher vitreous VEGF levels in patients with PDR 
than in controls (134 pg/mL vs 9 pg/mL, respectively), but 
there was no significant difference in serum VEGF levels 
Table 2 Correlation coefficient between vascular endothelial growth factor with HbA1C, Alb/Cr, and Alb in patients with proliferative 
diabetic retinopathy




Serum VEGF  
and HbA1C
Serum VEGF  
and Alb




Vitreous VEGF   
and Alb/Cr
P 0.012a 0.403b 0.837b 0.414b 0.017a 0.917b 0.842b
r 0.453 0.158 0.039 0.155 0.432 0.020 0.038
Notes: aP values were significant (P # 0.05); bP values were not significant (P . 0.05); data are presented as the mean ± standard deviation.
Abbreviations: VEGF, vascular endothelial growth factor; Alb, albumin; Cr, creatinine.
Table 1 Mean serum and vitreous fluid concentrations of vascular 
endothelial growth factor in PDR and NPDR patients
VEGF (pg/mL) PDR ( n = 30) NPDR (n = 35)
Vitreous fluid
All patientsa   383.1 ± 107.48   24.81 ± 1.85
Malea 325.81 ± 109.66   24.8 ± 2.24
Femalea 482.06 ± 228.97   24.3 ± 3.49
Serum
All patientsa 515.12 ± 44.8 343.58 ± 46.41
Malea   560.8 ± 1 297.25 ± 72.81
Femaleb 488.67 ± 48.27 424.12 ± 37.86
Notes: aP values were significant (P # 0.05); bP values were not significant (P . 0.05); 
data are presented as means ± standard deviation.
Abbreviations:  VEGF,  vascular  endothelial  growth  factor;  PDR,  proliferative 
diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy.
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(177 pg/mL vs 170 pg/mL).26 In another similar study by 
Malik et al in 11 patients with PDR and 23 controls, vitreous 
VEGF levels were higher in cases (720 pg/mL vs 180 pg/mL, 
respectively).27 In a study by Hernandez et al of 23 PDR 
patients and 17 controls, vitreous VEGF levels in the cases 
were higher than in controls (142 pg/mL vs 9 pg/mL) but 
there was no significant difference in serum VEGF levels 
(150 pg/mL vs 120 pg/mL).28 In a study by Simo et al in 
37 PDR patients and 21 controls, the vitreous VEGF level in 
the cases was higher than in controls (138 pg/mL vs 9 pg/mL) 
but there was no significant difference in the serum VEGF 
level (130 pg/mL vs 160 pg/mL).29 Watanabe et al, in their 
study of 41 PDR patients and 18 nondiabetic patients, showed 
that vitreous VEGF levels in PDR patients was higher than in 
nondiabetics (812 pg/mL vs 17 pg/mL).30 In a similar study 
by Sydorova and Lee, the serum and vitreous VEGF levels 
in PDR patients were higher than in controls.31
Hogeboom Van Buggenum et al compared 39 PDR 
patients with 11 controls, and reported mean vitreous VEGF 
levels of 1134 pg/mL and 59 pg/mL, respectively. This dif-
ference was statistically significant.32 In a similar study by 
Aiello et al in 70 PDR patients and 25 controls, vitreous 
VEGF levels in cases were higher than in controls (360 pg/
mL vs 100 pg/mL).33 Deng et al compared 27 PDR patients 
with 14 control patients, and found mean vitreous VEGF 
levels of 410 pg/mL and 17 pg/mL, respectively. This differ-
ence was statistically significant.34 In a study by Ambati et al 
in 22 PDR patients and 28 controls, the vitreous VEGF 
levels in cases were higher than in controls (1759 pg/mL vs 
27 pg/mL, respectively).35 In a study by Zhou and Zhang in 
19 PDR patients and seven controls, vitreous VEGF levels in 
cases were higher than in controls (566 pg/mL vs 350 pg/mL, 
respectively).36 Adamis et al also reported similar results.37 
In a study by Burgos et al in 20 PDR patients and 13 control 
patients, the vitreous VEGF level in cases was higher than in 
controls (175 pg/mL vs 9 pg/mL) but there was no significant 
difference in serum VEGF level.38
Almost all studies performed in this field until now are 
mentioned above. As can be seen, in all studies, the vitreous 
VEGF level in PDR patients was significantly higher than 
in controls. Serum VEGF levels are inconsistent, in the 
summarized results of other studies, the mean vitreous VEGF 
levels in PDR patients are 623 (138–1759) pg/mL and mean 
serum VEGF levels in PDR patients are 234 (120–509) pg/mL. 
The results of our study are also in the above range, but it 
should be noted that current results are calculated based on 
the level of vitreous proteins. Selecting vitreous proteins for 
measurement eliminates confounding factors and increases the 
accuracy of the results. This is one of the strong points of the 
current study. Burgos et al in their study showed that there was 
no significant correlation between serum and vitreous VEGF 
levels. They believe that all vitreous VEGF is made inside the 
eye and the serum emission is absent or negligible.38
In our study, we observed a high and significant correla-
tion between serum and vitreous VEGF levels (P = 0.012 
Table 3 Comparison of serum and vitreous vascular endothelial 





Serum VEGF  
(pg/mL)
524.65 ± 247.43 567.22 ± 207.73 105.00 ± 23.75
Vitreous VEGF  
(pg/mL)
250.53 ± 412.217 441.70 ± 624.21 383.10 ± 588.69
Note: Data are presented as the mean ± standard deviation.
Abbreviation: VEGF, vascular endothelial growth factor.
Table  4  Comparison  of  serum  and  vitreous  VEGF  levels  in 




Serum VEGF  
(pg/mL)
105.00 ± 23.75 556.35 ± 232.85 525.97 ± 226.70
Vitreous VEGF  
(pg/mL)
996.35 ± 1391.09 324.22 ± 536.69 383.10 ± 588.69
Note: Data are presented as means ± SD.
Abbreviation: VEGF, vascular endothelial growth factor.
Table 5 Comparison of serum and vitreous vascular endothelial 





Serum VEGF  
(pg/mL)
439.83 ± 272.91 533.77 ± 232.32 557.77 ± 256.57
Vitreous VEGF  
(pg/mL)
125.42 ± 124.78 648.53 ± 775.67 176.28 ± 192.62
Note: Data are presented as the mean ± standard deviation.
Abbreviation: VEGF, vascular endothelial growth factor.
Table 6 Serum and vitreous level of vascular endothelial growth 
factor based on duration of diabetes
Duration of diabetes Level of vitreous  
VEGF
Level of serum   
VEGF
More than 10 years 457.68 ± 634.66 512.45 ± 252.39
Less than 10 years   84.78 ± 153.76 525.80 ± 237.74
Note: Data are presented as the mean ± standard deviation.
Abbreviation: VEGF, vascular endothelial growth factor.
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and r = 0.453), and serum VEGF levels were higher in PDR 
patients than control patients. This is in contrast with results 
reported by other investigators. However, to reach firm 
conclusions in this regard, we suggest further studies. The 
current study showed that the vitreous VEGF level has no 
significant correlation with treatment of diabetes, glycemic 
control, severity of nephropathy, duration of diabetes, ACR 
ratio, severity of retinopathy, or HbA1c level (P . 0.05). As 
far as we have identified, few studies have been performed 
in this field. Malik et al in their study indicated that there 
was no significant correlation between HbA1c levels and 
the vitreous level of VEGF.27 Shinoda et al in another study 
showed that there was no significant correlation between the 
vitreous VEGF level and type and duration of diabetes, type 
of treatment, HbA1c level, and renal dysfunction.39
With regard to the correlation between the vitreous 
VEGF level and the severity of retinopathy, existing studies 
have indicated that the level of this substance in cases of 
active disease is more than in inactive disease, but there is 
not any study similar to our study.25,26,29 On the other hand, 
in our study, the serum level of VEGF was low in patients 
on oral therapy, those with good glycemic control, and the 
first stage of diabetic nephropathy. Another significant and 
positive correlation was observed between the level of this 
factor and serum ACR. There is no similar study in this field. 
To confirm these cases, we need to perform more research. 
In summary, the mean level of VEGF in serum and vitreous 
in patients with retinopathy was significantly higher than in 
patients with PDR. A significant and positive correlation was 
found between serum and vitreous VEGF levels.
The mean ratio of urinary albumin to serum creatinine and 
serum VEGF in patients with oral agent therapy with good 
glycemic control, in the mild stages of diabetic nephropathy 
were low. There was no correlation between serum and vitre-
ous VEGF levels with severity of retinopathy and diabetes 
duration. A significant and positive correlation was seen 
between serum VEGF level and level of albuminuria/creati-
nine. However, there was no significant correlation between 
serum or vitreous VEGF levels and the level of HbA1c.
The serum VEGF levels in comparison with the vitre-
ous VEGF levels is a good factor to determine the status of 
patients with proliferative diabetic retinopathy and as it is easy 
to measure, it is recommended that serum VEGF is quantified 
when patients are evaluated. Given the positive effect of good 
glycemic control on serum VEGF level, and VEGF association 
with eye lesions (in diabetic patients), the importance of appro-
priate blood sugar control is more apparent; further studies in 
this field with a larger sample size are recommended.
Conclusion
Serum and vitreous VEGF levels were significantly lower 
in patients on oral therapy, in patients with well co  ntrolled 
diabetes, and in those with early-stage retinopathy. 
Administration of anti-VEGF had a good effect in reducing 
the progression of PDR. In contrast with previous studies, 
we have demonstrated the ACR to be a factor predictive of 
retinopathy.
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